Cargando…

Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy

The J‐CAPRA score is an assessment tool which stratifies risk and predicts outcome of primary androgen deprivation therapy (ADT) using prostate‐specific antigen, Gleason score, and clinical TNM staging. Here, we aimed to assess the generalisability of this tool in multi‐ethnic Asians. Performance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Jasmine, Hinotsu, Shiro, Onozawa, Mizuki, Malek, Rohan, Sundram, Murali, Teh, Guan C., Ong, Teng‐Aik, Thevarajah, Shankaran, Zainal, Rohana, Khoo, Say C., Omar, Shamsuddin, Nasuha, Noor A., Akaza, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774710/ https://www.ncbi.nlm.nih.gov/pubmed/33098372 http://dx.doi.org/10.1002/cam4.3548

Ejemplares similares

Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countries
por: Lim, Jasmine, et al.
Publicado: (2021)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
por: Akaza, Hideyuki, et al.
Publicado: (2013)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
por: Blas, Leandro, et al.
Publicado: (2021)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
por: Ueno, Satoru, et al.
Publicado: (2018)

Prostate cancer in multi‐ethnic Asian men: Real‐world experience in the Malaysia Prostate Cancer (M‐CaP) Study
por: Lim, Jasmine, et al.
Publicado: (2021)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
por: Taguchi, Satoru, et al.
Publicado: (2023)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Lacrimal sac adenocarcinoma managed with androgen deprivation
por: Abramson, David H., et al.
Publicado: (2020)

Asian trends in primary androgen depletion therapy on prostate cancer
por: Akaza, Hideyuki
Publicado: (2013)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Detection and Cloning of a Protein Recognized by Anti‐human Prostate‐specific Antigen (PSA) Antibody in the Rat Ventral Prostate
por: Onozawa, Mizuki, et al.
Publicado: (2001)

Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management
por: Akaza, Hideyuki, et al.
Publicado: (2014)

Report of the third Asian Prostate Cancer study meeting
por: Lojanapiwat, Bannakij, et al.
Publicado: (2019)

Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration‐resistant prostate cancer: Real‐world experience in the Southeast Asian cohort
por: Lim, Jasmine, et al.
Publicado: (2020)

“Thumb's off” for acrometastasis of renal cell carcinoma: Is there a role for acrometastasectomy in the era of targeted therapy?
por: Lechmiannandan, Sivaneswaran, et al.
Publicado: (2018)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Ethnicity Is an Independent Determinant of Age-Specific PSA Level: Findings from a Multiethnic Asian Setting
por: Lim, Jasmine, et al.
Publicado: (2014)

Cardiovascular Risk Factors and Ethnicity Are Independent Factors Associated with Lower Urinary Tract Symptoms
por: Lim, Jasmine, et al.
Publicado: (2015)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Melt Rheological Behavior and Morphology of Poly(ethylene oxide)/Natural Rubber-graft-Poly(methyl methacrylate) Blends
por: Zainal, Nurul Fatahah Asyqin, et al.
Publicado: (2020)

Significant financial differences of chemical and surgical androgen deprivation in a contemporary cohort
por: Paul, Charles J., et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting
por: Kim, Choung-Soo, et al.
Publicado: (2017)

Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial
por: Oyama, Masafumi, et al.
Publicado: (2017)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Transcriptome Analysis of the Capra hircus Ovary
por: Zhao, Zhong Quan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bi2c8irbg4jrlkps57msm1n8d3